Steffen Thirstrup

1.0k total citations
39 papers, 644 citations indexed

About

Steffen Thirstrup is a scholar working on Economics and Econometrics, Molecular Biology and Physiology. According to data from OpenAlex, Steffen Thirstrup has authored 39 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 9 papers in Molecular Biology and 8 papers in Physiology. Recurrent topics in Steffen Thirstrup's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Asthma and respiratory diseases (6 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Steffen Thirstrup is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Asthma and respiratory diseases (6 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Steffen Thirstrup collaborates with scholars based in Denmark, Netherlands and United States. Steffen Thirstrup's co-authors include Jesper Sonne, Mogens Brandt Kristensen, Lars Bjerrum, Jens Erik Nielsen‐Kudsk, Camille Vleminckx, Christian K. Schneider, Jean‐Hugues Trouvin, Iordanis Gravanis, Falk Ehmann and Martina Weise and has published in prestigious journals such as The Lancet, Nature Biotechnology and The Journal of Infectious Diseases.

In The Last Decade

Steffen Thirstrup

37 papers receiving 620 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steffen Thirstrup Denmark 13 160 140 107 97 84 39 644
Marina Petrović Serbia 12 55 0.3× 95 0.7× 144 1.3× 50 0.5× 41 0.5× 65 585
Cristina Aguilera Spain 10 84 0.5× 106 0.8× 36 0.3× 110 1.1× 53 0.6× 54 690
Francesca Venturini Italy 13 97 0.6× 123 0.9× 70 0.7× 275 2.8× 55 0.7× 38 798
G Lagier France 12 78 0.5× 124 0.9× 146 1.4× 73 0.8× 57 0.7× 57 1.0k
Rolin L. Wade United States 15 133 0.8× 45 0.3× 66 0.6× 47 0.5× 28 0.3× 80 637
Elaine Nguyen United States 16 88 0.6× 104 0.7× 70 0.7× 74 0.8× 43 0.5× 67 922
Antonio Gimeno‐Miguel Spain 17 111 0.7× 126 0.9× 306 2.9× 45 0.5× 21 0.3× 51 786
Ken Wong United States 12 98 0.6× 100 0.7× 58 0.5× 89 0.9× 14 0.2× 22 644
Rajul A. Patel United States 14 84 0.5× 149 1.1× 37 0.3× 100 1.0× 47 0.6× 37 615
Heather Lochnan Canada 15 61 0.4× 104 0.7× 80 0.7× 177 1.8× 26 0.3× 55 876

Countries citing papers authored by Steffen Thirstrup

Since Specialization
Citations

This map shows the geographic impact of Steffen Thirstrup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Thirstrup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Thirstrup more than expected).

Fields of papers citing papers by Steffen Thirstrup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Thirstrup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Thirstrup. The network helps show where Steffen Thirstrup may publish in the future.

Co-authorship network of co-authors of Steffen Thirstrup

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Thirstrup. A scholar is included among the top collaborators of Steffen Thirstrup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Thirstrup. Steffen Thirstrup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Costa, Enrico, Antonella Isgrò, Anna M.G. Pasmooij, et al.. (2025). Addressing global regulatory challenges in rare disease drug development. Drug Discovery Today. 30(10). 104462–104462.
2.
Arlett, Peter, Patrice Verpillat, Paolo Foggi, et al.. (2025). Clinical Evidence 2030. Clinical Pharmacology & Therapeutics. 117(4). 884–886. 5 indexed citations
3.
Browne, K, Ewa Bałkowiec-Iskra, André Elferink, et al.. (2025). Applying the EU Regulatory Framework to Determine the Benefit–Risk Profile of Psychedelics. ACS Pharmacology & Translational Science. 8(8). 2830–2838.
4.
Spall, Harriette G.C. Van, Arnaud Bastien, Bernard J. Gersh, et al.. (2024). The role of early-phase trials and real-world evidence in drug development. Nature Cardiovascular Research. 3(2). 110–117. 3 indexed citations
5.
6.
Liechti, Matthias E., Kim P. C. Kuypers, David Nutt, et al.. (2024). Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects. Neuroscience Applied. 3. 103938–103938. 6 indexed citations
7.
Salmikangas, Paula, et al.. (2023). Potency testing of cell and gene therapy products. Frontiers in Medicine. 10. 1190016–1190016. 17 indexed citations
8.
Butlen‐Ducuing, Florence, Marion Haberkamp, Ewa Bałkowiec-Iskra, et al.. (2023). The therapeutic potential of psychedelics: the European regulatory perspective. The Lancet. 401(10378). 714–716. 20 indexed citations
9.
Coelho, Ana Cláudia, et al.. (2023). Tuberculosis medicines for children in Europe: an unmet medical need. ERJ Open Research. 9(4). 730–2022. 1 indexed citations
10.
Tarp, Simon, Daniel E. Furst, Maarten Boers, et al.. (2016). Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Lara D. Veeken. 56(3). kew442–kew442. 46 indexed citations
11.
Simões, Eric A. F., John P. DeVincenzo, Michael Boeckh, et al.. (2015). Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics. The Journal of Infectious Diseases. 211(suppl 1). S1–S20. 97 indexed citations
12.
George, Elisabeth, Anne d’Andon, Steffen Thirstrup, et al.. (2012). Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. Value in Health. 15(6). 954–960. 47 indexed citations
13.
Glintborg, Dorte, et al.. (2012). Danish physicians’ preferences for prescribing escitalopram over citalopram and sertraline to treatment-naïve patients: a national, register-based study. European Journal of Clinical Pharmacology. 69(5). 1167–1171. 4 indexed citations
14.
Aagaard, Lise, Steffen Thirstrup, & Ebba Holme Hansen. (2009). Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. Pharmacoepidemiology and Drug Safety. 18(5). 401–411. 4 indexed citations
15.
Thirstrup, Steffen, et al.. (2008). Combined intervention programme reduces inappropriate prescribing in elderly patients exposed to polypharmacy in primary care. European Journal of Clinical Pharmacology. 65(2). 199–207. 69 indexed citations
16.
Thirstrup, Steffen, et al.. (2007). Prevalence of inappropriate prescribing in primary care. Pharmacy World & Science. 29(3). 109–115. 54 indexed citations
17.
Thirstrup, Steffen. (2000). Control of airway smooth muscle tone. I - Electrophysiology and contractile mediators. Respiratory Medicine. 94(4). 328–336. 14 indexed citations
18.
Thirstrup, Steffen, Ronald Dahl, & F. Nielsen‐Kudsk. (1997). Interaction between prostaglandins and selective phosphodiesterase inhibitors in isolated guinea-pig trachea in vitro. European Journal of Pharmacology. 333(2-3). 215–221. 4 indexed citations
19.
Nielsen‐Kudsk, Jens Erik, Søren Mellemkjær, & Steffen Thirstrup. (1994). Inhibition by Cromakalim, Pinacidil, Terbutaline, Theophylline and Verapamil of Non-cholinergic Nerve-mediated Contractions of Guinea-pig Isolated Bronchi. Pulmonary Pharmacology. 7(5). 285–292. 5 indexed citations
20.
Thirstrup, Steffen & Jens Erik Nielsen‐Kudsk. (1992). Effects of K+ channel blockers on the relaxant action of dihydralazine, cromakalim and nitroprusside in isolated rabbit femoral arteries. European Journal of Pharmacology. 215(2-3). 177–183. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Petrović Breakdown of academic impact, for papers by Cristina Aguilera Breakdown of academic impact, for papers by Francesca Venturini Breakdown of academic impact, for papers by G Lagier Breakdown of academic impact, for papers by Rolin L. Wade Breakdown of academic impact, for papers by Elaine Nguyen Breakdown of academic impact, for papers by Antonio Gimeno‐Miguel Breakdown of academic impact, for papers by Ken Wong Breakdown of academic impact, for papers by Rajul A. Patel Breakdown of academic impact, for papers by Heather Lochnan
Rankless by CCL
2026